Cargando…

RPS6KA5 methylation predict response to 6-week treatment for adolescent MDD patients

OBJECTIVE: We aimed to investigate the effect of differentially methylated genes and chronic childhood stress on the development of depressive symptoms in Chinese adolescents, as well as to test whether methylation at baseline can be used as a predictor of remission at follow-up after six weeks of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Peiwei, Tao, Yuanmei, Zhang, Hang, Jin, Meijiang, Xu, Hanmei, Zou, Shoukang, Deng, Fang, Huang, Lijuan, Zhang, Hong, Wang, Xiaolan, Tang, Xiaowei, Dong, Zaiquan, Wang, Yanping, Yin, Li, Sun, Xueli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392312/
https://www.ncbi.nlm.nih.gov/pubmed/35986314
http://dx.doi.org/10.1186/s12888-022-04196-4
_version_ 1784771035494612992
author Xu, Peiwei
Tao, Yuanmei
Zhang, Hang
Jin, Meijiang
Xu, Hanmei
Zou, Shoukang
Deng, Fang
Huang, Lijuan
Zhang, Hong
Wang, Xiaolan
Tang, Xiaowei
Dong, Zaiquan
Wang, Yanping
Yin, Li
Sun, Xueli
author_facet Xu, Peiwei
Tao, Yuanmei
Zhang, Hang
Jin, Meijiang
Xu, Hanmei
Zou, Shoukang
Deng, Fang
Huang, Lijuan
Zhang, Hong
Wang, Xiaolan
Tang, Xiaowei
Dong, Zaiquan
Wang, Yanping
Yin, Li
Sun, Xueli
author_sort Xu, Peiwei
collection PubMed
description OBJECTIVE: We aimed to investigate the effect of differentially methylated genes and chronic childhood stress on the development of depressive symptoms in Chinese adolescents, as well as to test whether methylation at baseline can be used as a predictor of remission at follow-up after six weeks of treatment. METHODS: After recruiting 87 MDD patients and 53 healthy controls, we compared demographic and baseline clinical characteristics. The Childhood Chronic Stress Questionnaire was used to assess stress caused by early-life events. MDD patients underwent six weeks of treatment, and response to treatment was assessed using the Beck Depression Inventory-II. In addition, four MDD patients and five controls were randomly chosen for genome-wide methylation analysis. RESULTS: The gene RPS6KA5 showed significant methylation differences between the two groups. Severity of chronic childhood stress was significantly associated with increased risk of depression in adolescents, but not with treatment response. Baseline RPS6KA5 methylation can predict remission after six weeks of treatment. We did not observe any interaction between RPS6KA5 methylation and chronic childhood stress. CONCLUSIONS: Our results suggest that RPS6KA5 methylation can be used as a predictor of response to treatment in adolescent MDD patients. Here we offer new evidence for the role of epigenetics in early response to treatment of depression. TRIAL REGISTRATION: ChiCTR, ChiCTR2000033402, 31/05/2020, http://www.chictr.org.cn/index.aspx SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-022-04196-4.
format Online
Article
Text
id pubmed-9392312
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93923122022-08-21 RPS6KA5 methylation predict response to 6-week treatment for adolescent MDD patients Xu, Peiwei Tao, Yuanmei Zhang, Hang Jin, Meijiang Xu, Hanmei Zou, Shoukang Deng, Fang Huang, Lijuan Zhang, Hong Wang, Xiaolan Tang, Xiaowei Dong, Zaiquan Wang, Yanping Yin, Li Sun, Xueli BMC Psychiatry Research OBJECTIVE: We aimed to investigate the effect of differentially methylated genes and chronic childhood stress on the development of depressive symptoms in Chinese adolescents, as well as to test whether methylation at baseline can be used as a predictor of remission at follow-up after six weeks of treatment. METHODS: After recruiting 87 MDD patients and 53 healthy controls, we compared demographic and baseline clinical characteristics. The Childhood Chronic Stress Questionnaire was used to assess stress caused by early-life events. MDD patients underwent six weeks of treatment, and response to treatment was assessed using the Beck Depression Inventory-II. In addition, four MDD patients and five controls were randomly chosen for genome-wide methylation analysis. RESULTS: The gene RPS6KA5 showed significant methylation differences between the two groups. Severity of chronic childhood stress was significantly associated with increased risk of depression in adolescents, but not with treatment response. Baseline RPS6KA5 methylation can predict remission after six weeks of treatment. We did not observe any interaction between RPS6KA5 methylation and chronic childhood stress. CONCLUSIONS: Our results suggest that RPS6KA5 methylation can be used as a predictor of response to treatment in adolescent MDD patients. Here we offer new evidence for the role of epigenetics in early response to treatment of depression. TRIAL REGISTRATION: ChiCTR, ChiCTR2000033402, 31/05/2020, http://www.chictr.org.cn/index.aspx SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12888-022-04196-4. BioMed Central 2022-08-19 /pmc/articles/PMC9392312/ /pubmed/35986314 http://dx.doi.org/10.1186/s12888-022-04196-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Xu, Peiwei
Tao, Yuanmei
Zhang, Hang
Jin, Meijiang
Xu, Hanmei
Zou, Shoukang
Deng, Fang
Huang, Lijuan
Zhang, Hong
Wang, Xiaolan
Tang, Xiaowei
Dong, Zaiquan
Wang, Yanping
Yin, Li
Sun, Xueli
RPS6KA5 methylation predict response to 6-week treatment for adolescent MDD patients
title RPS6KA5 methylation predict response to 6-week treatment for adolescent MDD patients
title_full RPS6KA5 methylation predict response to 6-week treatment for adolescent MDD patients
title_fullStr RPS6KA5 methylation predict response to 6-week treatment for adolescent MDD patients
title_full_unstemmed RPS6KA5 methylation predict response to 6-week treatment for adolescent MDD patients
title_short RPS6KA5 methylation predict response to 6-week treatment for adolescent MDD patients
title_sort rps6ka5 methylation predict response to 6-week treatment for adolescent mdd patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392312/
https://www.ncbi.nlm.nih.gov/pubmed/35986314
http://dx.doi.org/10.1186/s12888-022-04196-4
work_keys_str_mv AT xupeiwei rps6ka5methylationpredictresponseto6weektreatmentforadolescentmddpatients
AT taoyuanmei rps6ka5methylationpredictresponseto6weektreatmentforadolescentmddpatients
AT zhanghang rps6ka5methylationpredictresponseto6weektreatmentforadolescentmddpatients
AT jinmeijiang rps6ka5methylationpredictresponseto6weektreatmentforadolescentmddpatients
AT xuhanmei rps6ka5methylationpredictresponseto6weektreatmentforadolescentmddpatients
AT zoushoukang rps6ka5methylationpredictresponseto6weektreatmentforadolescentmddpatients
AT dengfang rps6ka5methylationpredictresponseto6weektreatmentforadolescentmddpatients
AT huanglijuan rps6ka5methylationpredictresponseto6weektreatmentforadolescentmddpatients
AT zhanghong rps6ka5methylationpredictresponseto6weektreatmentforadolescentmddpatients
AT wangxiaolan rps6ka5methylationpredictresponseto6weektreatmentforadolescentmddpatients
AT tangxiaowei rps6ka5methylationpredictresponseto6weektreatmentforadolescentmddpatients
AT dongzaiquan rps6ka5methylationpredictresponseto6weektreatmentforadolescentmddpatients
AT wangyanping rps6ka5methylationpredictresponseto6weektreatmentforadolescentmddpatients
AT yinli rps6ka5methylationpredictresponseto6weektreatmentforadolescentmddpatients
AT sunxueli rps6ka5methylationpredictresponseto6weektreatmentforadolescentmddpatients